Results 41 to 50 of about 1,016,101 (284)

Combinatorial functions of two chimeric antibodies directed to human CD4 and one directed to the a-chain of the human interleukin-2 receptor [PDF]

open access: yes, 1992
The general feasibility of chimerization of monoclonal antibodies (mAbs) has already been shown for a large number of them. In order to evaluate in vitro parameters relevant to immunosuppressive therapy, we have chimerized and synthesized two anti-CD4 ...
Schwirzke, Marina   +10 more
core   +1 more source

Tumor therapy with T-cells with chimeric antigen receptors

open access: yes, 2023
Žive stanice su najnovija generacija bioloških lijekova tzv. biofarmaceutika, kojima pripadaju T-stanice s kimernim antigenskim receptorima (CAR – engl. chimeric antigen receptor) namijenjene terapiji tumora.
Grahek, Petra
core   +2 more sources

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Data from: Chimeric antigen receptors that trigger phagocytosis

open access: yes, 2018
Chimeric antigen receptors (CARs) are synthetic receptors that reprogram T cells to kill cancer. The success of CAR-T cell therapies highlights the promise of programmed immunity and suggests that applying CAR strategies to other immune cell lineages may
Headley, Mark B.   +7 more
core   +1 more source

Application progress on immunotherapy with chimeric antigen receptor T cell in patients with hematological malignancies

open access: yesHuli yanjiu, 2020
Reviewing application progress on immunotherapy with chimeric antigen receptor T cell(CAR⁃T) in patients with hematological malignancies from 4 aspects,such as collection,pretreatment,note on cell reinfusion,and treatment complication of chimeric antigen
MENG Rui, XU Li, WAN Ying
doaj  

The ubiquitin system in normal and infected germinal center B cells

open access: yesFEBS Letters, EarlyView.
The ubiquitin system plays a central role in germinal center (GC) B cells, influencing differentiation to long‐lived memory B cells. Oncogenic gammaherpesviruses gain access to memory B cells by establishing latency in GC B cells. Mapping ubiquitin mechanisms in normal and infected GC B cells will define specific molecular circuits in B cells germane ...
Destiny Davis   +2 more
wiley   +1 more source

Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma

open access: yesNature Communications, 2020
Chimeric antigen receptor (CAR)-based therapy for the treatment of liver cancer represents a promising therapeutic strategy. Here the authors show that CD147-targeting CAR-NK or CAR-T can induce anti-tumor activity against hepatocellular carcinoma in ...
Hsiang-chi Tseng   +14 more
doaj   +1 more source

Design of diversified chimeric antigen receptors through rational module recombination

open access: yesiScience, 2023
Summary: Chimeric antigen receptor (CAR)-T cells have shown great promise in cancer therapy. However, the anti-tumor efficiency is limited due to the CAR-induced T cell apoptosis or exhaustion.
Wen Si   +8 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

open access: yesMolecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary   +1 more
wiley   +1 more source

Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment

open access: yesFrontiers in Immunology
Adoptive T cell therapy has transformed cancer treatment, with chimeric antigen receptor (CAR) T cell therapy demonstrating remarkable clinical success in hematological malignancies.
Riley Rane   +13 more
doaj   +1 more source

Home - About - Disclaimer - Privacy